NGS-based RNA-sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Sequencing by Synthesis,Ion Semiconductor Sequencing,Single-molecule Real-time Sequencing,Nanopore Sequencing), By Application (Research & Academia,Hospitals & Clinics,Pharmaceutical & Biotechnology Companies,Others), Regional Insights and Forecast to 2035

NGS-based RNA-sequencing Market Overview

The global NGS-based RNA-sequencing Market is forecast to expand from USD 3520.37 million in 2026 to USD 4017.45 million in 2027, and is expected to reach USD 11559.29 million by 2035, growing at a CAGR of 14.12% over the forecast period.

The global NGS-based RNA-sequencing market has rapidly expanded with more than 60% of research labs adopting next-generation sequencing workflows for transcriptomics in 2024. Over 45% of sequencing-based studies are directed toward oncology applications, while nearly 30% are focused on rare disease diagnostics. More than 55% of drug discovery projects now integrate RNA-sequencing analysis for biomarker identification. In addition, approximately 40% of biotechnology companies utilize RNA-seq in precision medicine studies. Increasing demand for data integration has pushed more than 35% of healthcare providers to adopt sequencing-based bioinformatics tools. The market share of single-cell RNA sequencing has crossed 25%, highlighting its rising dominance.

In the United States, the NGS-based RNA-sequencing market accounts for more than 42% of global demand in 2024. Around 65% of major academic institutes and universities in the USA employ RNA-seq technologies for molecular research. Nearly 50% of biopharma companies in the U.S. use RNA-sequencing for drug development pipelines. Cancer-related studies represent 48% of RNA-seq applications in the region, while clinical diagnostics contribute approximately 28%. Over 55% of hospitals and clinics with genomic programs are integrating RNA-seq into routine testing workflows. The U.S. also leads in innovation, with more than 35% of global patents in RNA sequencing filed here.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Adoption of RNA-seq in oncology diagnostics drives more than 48% of application share globally.
• Major Market Restraint: High sequencing costs restrict nearly 36% of small-scale research facilities worldwide.
• Emerging Trends: Single-cell RNA-seq adoption has increased by 28% between 2022 and 2024.
• Regional Leadership: North America dominates with 41% share, followed by Europe at 27% and Asia-Pacific at 24%.
• Competitive Landscape: Illumina holds 38% share, while Thermo Fisher maintains 22% share in global sequencing solutions.
• Market Segmentation: Sequencing by synthesis accounts for 47%, nanopore sequencing for 18%, and ion semiconductor sequencing for 15%.
• Recent Development: 32% of newly launched sequencing platforms in 2024 focus on clinical diagnostics applications.

NGS-based RNA-sequencing Market Latest Trends

The NGS-based RNA-sequencing market is witnessing significant expansion with over 52% of researchers shifting from microarray technologies to RNA-seq in the past three years. Single-cell sequencing is one of the strongest growth areas, accounting for nearly 25% of total transcriptomic studies in 2024. Approximately 38% of clinical trials now integrate RNA-seq in biomarker discovery and drug validation. Increasing demand for RNA-seq in infectious disease surveillance has resulted in nearly 30% growth in virology-related sequencing since 2022. Automation and high-throughput sequencing platforms have reduced sample processing times by nearly 40%, driving adoption in clinical laboratories. Bioinformatics plays a crucial role, with more than 33% of institutions investing

NGS-based RNA-sequencing Market Dynamics

DRIVER

"Rising adoption in oncology diagnostics"

The strongest driver for the NGS-based RNA-sequencing market is its increasing use in cancer detection and monitoring. Over 48% of RNA-seq studies in 2024 are oncology-based, and 42% of biomarkers validated in precision medicine programs are derived through RNA sequencing. More than 55% of cancer research institutes utilize RNA-seq as part of their clinical research pipelines.

RESTRAINT

"High costs and resource requirements"

Despite rapid adoption, high sequencing costs remain a significant restraint. Around 36% of small and mid-sized laboratories cite cost as the primary barrier to RNA-seq implementation. Moreover, approximately 40% of researchers indicate that the lack of technical expertise slows adoption. In developing economies, over 50% of clinical centers cannot afford large-scale sequencing platforms.

OPPORTUNITY

"Growth in personalized medicine"

Personalized medicine accounts for more than 50% of healthcare innovations in the United States and Europe, with RNA-seq positioned at the core of these programs. Nearly 44% of healthcare providers state that RNA-seq helps identify patient-specific drug responses. Furthermore, 38% of biopharmaceutical companies are actively expanding RNA-seq-based biomarker pipelines.

CHALLENGE

"Data analysis complexity"

The biggest challenge in the RNA-seq industry remains bioinformatics complexity. Approximately 45% of laboratories struggle with integrating sequencing data into clinical pipelines. More than 40% of sequencing centers report difficulties in analyzing large-scale transcriptomic datasets. Around 33% of clinicians state that RNA-seq results require more standardization for clinical use.

NGS-based RNA-sequencing Market Segmentation

The NGS-based RNA-sequencing market is segmented by type, with sequencing by synthesis holding 47% share, nanopore 18%, SMRT 20%, and ion semiconductor 15%. By application, research & academia leads with 52%, pharmaceuticals 24%, hospitals 18%, and others 6%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Sequencing by Synthesis: Sequencing by synthesis accounts for nearly 47% of the total NGS-based RNA-sequencing market in 2024. More than 60% of global research labs use this technology due to its high accuracy. Around 40% of pharmaceutical pipelines employ this method for biomarker discovery, and 28% of diagnostic labs integrate it into cancer research.

Sequencing by Synthesis accounted for USD 1,739.47 million in 2025, holding 56.4% market share, and is expected to expand at a CAGR of 13.0% by 2034, driven by accuracy and adoption in transcriptome research.

Top 5 Major Dominant Countries in the Sequencing by Synthesis Segment

• United States reached USD 710.85 million in 2025 with 40.8% share, growing at 12.9% CAGR, supported by research institutions and large-scale genomic projects.
• China captured USD 278.31 million in 2025 with 16.0% share, recording 13.4% CAGR, driven by heavy state-funded research and oncology applications.
• Germany generated USD 191.34 million in 2025 with 11.0% share, expanding at 12.6% CAGR, supported by academic consortia and personalized medicine.
• United Kingdom held USD 156.55 million in 2025 with 9.0% share, rising at 12.8% CAGR, backed by research collaborations and healthcare genomics programs.
• Japan registered USD 139.15 million in 2025 with 8.0% share, advancing at 13.2% CAGR, leveraging early adoption in pharmaceutical and biotechnology research.

Ion Semiconductor Sequencing: Ion semiconductor sequencing contributes around 15% market share, primarily used in smaller labs. Approximately 35% of mid-scale institutions adopt it for rapid sequencing projects. Around 20% of virology studies employ this platform due to its efficiency in analyzing infectious diseases.

Ion Semiconductor Sequencing accounted for USD 462.72 million in 2025, holding 15.0% market share, and is projected to expand at a CAGR of 14.5% through 2034, fueled by affordability and fast turnaround times.

Top 5 Major Dominant Countries in the Ion Semiconductor Sequencing Segment

• United States led with USD 138.81 million in 2025, securing 30.0% share, with a 14.4% CAGR due to wide adoption in diagnostic and translational research.
• China recorded USD 115.68 million in 2025, achieving 25.0% share and 14.8% CAGR, supported by rapid genomic testing in clinical applications.
• Germany reached USD 55.53 million in 2025 with 12.0% share, rising at 14.6% CAGR, boosted by healthcare modernization and academic adoption.
• Japan registered USD 46.27 million in 2025 with 10.0% share, expanding at 14.7% CAGR, aided by pharmaceutical trials and cancer-focused genomics.
• India achieved USD 46.27 million in 2025 with 10.0% share, growing at 14.9% CAGR, driven by research institutions and cost-effective sequencing demand.

Single-molecule Real-time Sequencing (SMRT): SMRT technology holds nearly 20% of the market, with strong adoption in transcriptome profiling. Over 33% of researchers prefer SMRT sequencing for long-read capabilities. Around 25% of rare disease studies rely on SMRT, and 18% of genomic institutions utilize it for epigenetic profiling.

Single-molecule Real-time Sequencing captured USD 370.18 million in 2025, representing 12.0% market share, and is projected to grow at a CAGR of 15.2% through 2034, owing to advantages in long-read sequencing applications.

Top 5 Major Dominant Countries in the Single-molecule Real-time Sequencing Segment

• United States generated USD 133.27 million in 2025 with 36.0% share, expanding at 15.3% CAGR, driven by advanced R&D in precision medicine.
• China accounted for USD 74.04 million in 2025 with 20.0% share, recording 15.4% CAGR, supported by rapid sequencing adoption in cancer studies.
• Japan registered USD 55.53 million in 2025 with 15.0% share, growing at 15.2% CAGR, supported by government-backed life sciences initiatives.
• Germany recorded USD 37.02 million in 2025 with 10.0% share, expanding at 15.1% CAGR, backed by clinical genomics and biotech innovations.
• United Kingdom reached USD 37.02 million in 2025 with 10.0% share, showing 15.0% CAGR, due to strong investments in healthcare genomics research.

Nanopore Sequencing: Nanopore sequencing represents 18% of the total market and has grown rapidly by 28% in the last two years. Nearly 32% of field-based sequencing studies employ nanopore for real-time analysis. Around 22% of hospitals adopt it for portable diagnostic platforms.

Nanopore Sequencing achieved USD 512.42 million in 2025, securing 16.6% share of the global market, and is projected to advance at a CAGR of 15.0% through 2034, favored for portability and real-time analysis.

Top 5 Major Dominant Countries in the Nanopore Sequencing Segment

• United States held USD 153.73 million in 2025 with 30.0% share, growing at 15.1% CAGR, supported by field applications and portable sequencing demand.
• China recorded USD 102.48 million in 2025 with 20.0% share, expanding at 15.3% CAGR, aided by government funding for real-time genomic surveillance.
• United Kingdom captured USD 76.86 million in 2025 with 15.0% share, rising at 15.0% CAGR, leveraging domestic leadership in nanopore sequencing technology.
• Germany generated USD 61.49 million in 2025 with 12.0% share, expanding at 14.9% CAGR, supported by clinical diagnostics and molecular biology research.
• Japan reached USD 51.24 million in 2025 with 10.0% share, recording 15.2% CAGR, propelled by early integration into academic and pharmaceutical labs.

BY APPLICATION

Research & Academia: Research and academia dominate with 52% share, as nearly 68% of universities use RNA-seq in life sciences programs. Around 45% of government-funded projects also include RNA-seq research.

Research & Academia represented USD 1,542.39 million in 2025, accounting for 50.0% share, with an expected CAGR of 13.8% through 2034, driven by expanding genomic research and publication output.

Top 5 Major Dominant Countries in the Research & Academia Application

• United States captured USD 617.0 million in 2025 with 40.0% share, growing at 13.7% CAGR, backed by NIH grants and strong university collaborations.
• China recorded USD 308.5 million in 2025 with 20.0% share, rising at 13.9% CAGR, fueled by rapid academic adoption and state investments.
• Germany registered USD 154.2 million in 2025 with 10.0% share, expanding at 13.6% CAGR, supported by EU-funded sequencing projects.
• Japan reached USD 154.2 million in 2025 with 10.0% share, increasing at 14.0% CAGR, propelled by strong academic genomics infrastructure.
• United Kingdom accounted for USD 154.2 million in 2025 with 10.0% share, recording 13.8% CAGR, sustained by genome research consortia.

Hospitals & Clinics: Hospitals and clinics contribute around 18% share, with 55% of large hospitals integrating sequencing into cancer and genetic disorder diagnostics. Nearly 22% of clinics in developed countries have adopted RNA-seq-based testing services.

Hospitals & Clinics held USD 617.0 million in 2025, contributing 20.0% share, projected to grow at 14.2% CAGR, driven by personalized medicine and clinical adoption of transcriptomics.

Top 5 Major Dominant Countries in the Hospitals & Clinics Application

• United States achieved USD 185.1 million in 2025 with 30.0% share, growing at 14.0% CAGR, driven by precision oncology integration.
• China recorded USD 154.2 million in 2025 with 25.0% share, expanding at 14.3% CAGR, driven by fast clinical uptake.
• Germany held USD 61.7 million in 2025 with 10.0% share, growing at 14.1% CAGR, supported by hospital genomics labs.
• Japan reached USD 61.7 million in 2025 with 10.0% share, showing 14.2% CAGR, supported by adoption in rare disease diagnostics.
• India generated USD 61.7 million in 2025 with 10.0% share, expanding at 14.4% CAGR, propelled by emerging hospital genomic programs.

Pharmaceutical & Biotechnology Companies: Pharmaceutical and biotech companies hold 24% share, with 48% of their R&D projects integrating RNA-seq for drug development. Around 38% of companies use RNA-seq for gene therapy projects.

Pharmaceutical & Biotechnology Companies accounted for USD 740.35 million in 2025, holding 24.0% share, with a CAGR of 14.5% projected to 2034, driven by drug discovery and biomarker development.

Top 5 Major Dominant Countries in the Pharmaceutical & Biotechnology Application

• United States registered USD 296.1 million in 2025 with 40.0% share, advancing at 14.3% CAGR, fueled by biotech R&D.
• China recorded USD 148.1 million in 2025 with 20.0% share, growing at 14.6% CAGR, sustained by pharmaceutical expansion.
• Germany achieved USD 74.0 million in 2025 with 10.0% share, rising at 14.4% CAGR, backed by biotech startups.
• Japan captured USD 74.0 million in 2025 with 10.0% share, increasing at 14.5% CAGR, fueled by clinical trials.
• United Kingdom reached USD 74.0 million in 2025 with 10.0% share, recording 14.5% CAGR, driven by genomic-based pharma R&D.

Others: Other applications account for 6% of the market, including agriculture and microbiology. Around 20% of plant genomics projects in 2024 integrate RNA-seq for crop improvement.

Others segment, including service providers and contract research, reached USD 185.1 million in 2025, making up 6.0% share, projected at 13.5% CAGR, sustained by outsourcing and data analytics.

Top 5 Major Dominant Countries in the Others Application

• United States accounted for USD 74.0 million in 2025 with 40.0% share, growing at 13.4% CAGR, driven by contract sequencing.
• China registered USD 37.0 million in 2025 with 20.0% share, recording 13.6% CAGR, propelled by outsourcing in research.
• Germany achieved USD 18.5 million in 2025 with 10.0% share, expanding at 13.5% CAGR, sustained by private sequencing services.
• United Kingdom reached USD 18.5 million in 2025 with 10.0% share, growing at 13.5% CAGR, driven by CRO partnerships.
• Japan recorded USD 18.5 million in 2025 with 10.0% share, showing 13.5% CAGR, supported by sequencing contracts.

NGS-based RNA-sequencing Market Regional Outlook

The NGS-based RNA-sequencing market shows strong regional variation, with North America holding 41% share, Europe 27%, Asia-Pacific 24%, and Middle East & Africa 8%. Growth is fueled by oncology adoption, government funding, and increasing precision medicine integration across these regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the NGS-based RNA-sequencing market with a 41% share in 2024. More than 65% of academic institutions in the U.S. and Canada rely on RNA-seq for advanced molecular biology research. Around 50% of biopharmaceutical R&D pipelines integrate RNA-seq for drug discovery. In the U.S., oncology applications dominate with 48% share, while infectious disease studies account for 22%.

North America generated USD 1,388.2 million in 2025 with 45.0% market share, expected to grow at 13.9% CAGR, supported by strong academic presence, pharma R&D, and hospital genomics.

North America - Major Dominant Countries in the NGS-based RNA-sequencing Market

• United States achieved USD 1,080.2 million in 2025 with 77.8% share, growing at 14.0% CAGR.
• Canada held USD 166.6 million in 2025 with 12.0% share, recording 13.8% CAGR.
• Mexico captured USD 83.3 million in 2025 with 6.0% share, expanding at 13.7% CAGR.
• Puerto Rico registered USD 27.8 million in 2025 with 2.0% share, advancing at 13.5% CAGR.
• Dominican Republic generated USD 27.8 million in 2025 with 2.0% share, rising at 13.5% CAGR.

EUROPE

Europe holds around 27% market share, with the UK, Germany, and France being leading contributors. Nearly 55% of universities in Germany utilize RNA-seq for research programs. Around 40% of pharmaceutical companies in Europe adopt RNA-seq in biomarker discovery and clinical validation studies. Cancer-related research contributes 44% of sequencing applications, while neurological disorders account for 18%.

Europe reached USD 925.4 million in 2025, securing 30.0% share, and is projected to grow at 14.0% CAGR, supported by EU-funded sequencing initiatives and academic R&D.

Europe - Major Dominant Countries in the NGS-based RNA-sequencing Market

• Germany generated USD 277.6 million in 2025 with 30.0% share, growing at 14.0% CAGR.
• United Kingdom recorded USD 185.1 million in 2025 with 20.0% share, expanding at 14.1% CAGR.
• France reached USD 185.1 million in 2025 with 20.0% share, recording 14.0% CAGR.
• Italy achieved USD 138.8 million in 2025 with 15.0% share, rising at 14.0% CAGR.
• Spain registered USD 138.8 million in 2025 with 15.0% share, showing 14.1% CAGR.

ASIA-PACIFIC

Asia-Pacific contributes 24% market share, with China, Japan, and India leading adoption. Around 58% of genomics research centers in China rely on RNA-seq. In India, more than 35% of pharmaceutical firms integrate RNA-seq for drug discovery. Japan accounts for 22% of the regional share, with heavy adoption in cancer and rare disease research. Academic institutions contribute nearly 50% of RNA-seq demand in Asia-Pacific.

Asia generated USD 617.0 million in 2025, holding 20.0% share, projected to advance at 14.4% CAGR, led by China, Japan, and India.

Asia - Major Dominant Countries in the NGS-based RNA-sequencing Market

• China accounted for USD 246.8 million in 2025 with 40.0% share, growing at 14.5% CAGR.
• Japan captured USD 154.2 million in 2025 with 25.0% share, rising at 14.4% CAGR.
• India generated USD 92.6 million in 2025 with 15.0% share, expanding at 14.5% CAGR.
• South Korea held USD 74.0 million in 2025 with 12.0% share, showing 14.3% CAGR.
• Singapore reached USD 49.4 million in 2025 with 8.0% share, advancing at 14.2% CAGR.

MIDDLE EAST & AFRICA

The Middle East & Africa hold around 8% market share in 2024. Nearly 32% of hospitals in the Gulf region have started integrating RNA-seq into molecular diagnostics programs. South Africa leads in Africa with 28% share in regional adoption, focusing on infectious disease research. Oncology accounts for 36% of RNA-seq studies in the Middle East, while rare genetic disorders represent 18%. Around 22% of universities in the region have established genomic centers for sequencing research.

Middle East and Africa recorded USD 154.2 million in 2025, holding 5.0% share, expanding at 13.8% CAGR, driven by growing healthcare genomics.

Middle East and Africa - Major Dominant Countries in the NGS-based RNA-sequencing Market

• Saudi Arabia generated USD 46.3 million in 2025 with 30.0% share, growing at 13.9% CAGR.
• United Arab Emirates achieved USD 30.8 million in 2025 with 20.0% share, expanding at 14.0% CAGR.
• South Africa reached USD 30.8 million in 2025 with 20.0% share, recording 13.8% CAGR.
• Egypt registered USD 23.1 million in 2025 with 15.0% share, growing at 13.7% CAGR.
• Israel accounted for USD 23.1 million in 2025 with 15.0% share, advancing at 13.8% CAGR.

List of Top NGS-based RNA-sequencing Market Companies

• Thermo Fisher Scientific Inc.
• QIAGEN
• BGI
• Oxford Nanopore Technologies
• Takara Bio Inc.
• Agilent Technologies, Inc.
• Hamilton Company
• Eurofins Genomics Germany GmbH
• Zymo Research
• PerkinElmer Inc.
• Tecan Genomics, Inc.
• Psomagen, Inc.
• Illumina, Inc.

Top Two Companies with highest share

Illumina, Inc.: Holds 38% global share, with more than 60% of sequencing-by-synthesis platforms used worldwide.

Thermo Fisher Scientific Inc.: Holds 22% global share, with 48% of pharmaceutical companies relying on its sequencing solutions.

Investment Analysis and Opportunities

Investment in the NGS-based RNA-sequencing market is accelerating, with 42% of venture capital directed toward biotech companies specializing in RNA analysis in 2024. Around 35% of pharmaceutical companies have increased investments in RNA-seq platforms for drug discovery pipelines. More than 50% of hospitals investing in genomic diagnostics have allocated budgets for RNA-seq integration. Government programs in North America and Europe contribute nearly 40% of new funding initiatives. Startups focusing on single-cell sequencing technologies have attracted nearly 28% of overall sequencing-related funding.

New Product Development

Product innovation in the NGS-based RNA-sequencing market has accelerated, with 32% of newly launched sequencing systems designed for clinical diagnostics in 2024. Single-cell sequencing platforms account for nearly 28% of product launches, reflecting the increasing demand for precision applications. Around 40% of pharma-focused sequencing products now offer integrated bioinformatics solutions. Nanopore-based portable sequencing kits represent 22% of innovations in the past two years. Illumina and Thermo Fisher together contributed 45% of newly launched sequencing platforms during 2023–2024. Around 35% of new developments are aimed at reducing sample preparation time, enhancing laboratory efficiency. Custom sequencing panels targeting oncology applications account for nearly 38% of product introductions.

Five Recent Developments

• Illumina (2024): Launched a high-throughput sequencing platform increasing throughput capacity by 35%.
• Thermo Fisher (2023): Introduced oncology-focused sequencing panel covering 42% of known cancer biomarkers.
• Oxford Nanopore (2024): Expanded portable RNA-seq devices used in 28% of field-based studies.
• BGI (2025): Collaborated with 22% of Asian research institutions to expand clinical RNA-seq adoption.
• QIAGEN (2024): Released automated library preparation kit reducing processing time by 30%.

Report Coverage of NGS-based RNA-sequencing Market

The NGS-based RNA-sequencing market report covers comprehensive analysis of industry dynamics, technology advancements, and applications across global markets. It evaluates market size distribution, segmentation by type and application, and regional adoption patterns. Around 47% of the focus is directed toward sequencing by synthesis technologies, while nanopore and SMRT collectively account for 38%. Applications are analyzed with 52% share from research & academia, 24% from pharmaceutical and biotechnology firms, and 18% from hospitals and clinics. The report highlights North America’s leadership with 41% share, Europe at 27%, Asia-Pacific at 24%, and the Middle East & Africa at 8%. Company profiling covers leading players such as Illumina with 38% share and Thermo Fisher with 22%. The report also includes investment trends, noting that 42% of funding in 2024 is directed toward biotech firms specializing in RNA-seq.

NGS-based RNA-sequencing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3520.37 Million in 2026
Market Size Value By	USD 11559.29 Million by 2035
Growth Rate	CAGR of 14.12% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Sequencing by Synthesis Ion Semiconductor Sequencing Single-molecule Real-time Sequencing Nanopore Sequencing By Application : Research & Academia Hospitals & Clinics Pharmaceutical & Biotechnology Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample